IDiyas

For the Inventor, By the Inventor

Leverkusen, Germany

Michael Stegemann

USPTO Granted Patents = 10

Average Co-Inventor Count = 8.4

ph-index = 5

Forward Citations = 44(Granted Patents)


Location History:

  • Leverkusen, DE (1996 - 1997)
  • Shawnee Mission, KS (US) (1998)
  • Kansas City, MO (US) (1998 - 2001)

Company Filing History:

goldMedal10 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1996-2001

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6323213 - Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives (2001-11-27),
2. 6278013 - Optionally substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and their derivatives (2001-08-21),
3. 5998418 - Enrofloxacine injection or infusion solutions (1999-12-07),
4. 5854241 - Pyrido�3,2,1-I,J!�3,1!benzoxazine derivatives (1998-12-29),
5. 5744478 - Thiazolo �3,2-a! quinoline and thiazolo �3,2-a! naphthyridine derivatives (1998-04-28),
6. 5679675 - 8-amino-10-(azabicycloalkyl)-pyrido�1,2,3-d,e!�1,3,4!benzoxadiazine (1997-10-21),
7. 5659038 - 5-vinyl-and 5-ethinyl-quinolone- and -naphthyridone-carboxylic acids (1997-08-19),
8. 5618815 - 1,9-bridged thiazolo[3,2-a]quinoline derivatives (1997-04-08),
9. 5578604 - 5-vinyl- and 5-ethinyl-quinolone- carboxylic acids (1996-11-26),
10. 5508278 - Pyrido[1,2,3-D,E] [1,3,4]benzoxadiazine derivatives (1996-04-16),

Title: Michael Stegemann: Innovator in Pharmaceutical Chemistry

Introduction

Michael Stegemann is a prominent inventor based in Leverkusen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds. With a total of 10 patents to his name, Stegemann's work has had a considerable impact on the industry.

Latest Patents

Among his latest patents, Stegemann has developed possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and their derivatives. This invention relates to novel optionally substituted compounds that are useful in various pharmaceutical applications. The general formula (I) of these compounds highlights their potential in drug development.

Career Highlights

Stegemann is currently employed at Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. His innovative work has positioned him as a key figure in the research and development of new therapeutic agents. His contributions have not only advanced scientific knowledge but have also paved the way for new treatment options.

Collaborations

Throughout his career, Stegemann has collaborated with notable colleagues, including Heinz-Georg Wetzstein and Thomas Jaetsch. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Michael Stegemann's contributions to pharmaceutical chemistry exemplify the spirit of innovation in the field. His patents and collaborative efforts continue to influence the development of new therapeutic agents, showcasing the importance of research and invention in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…